Conclusion: A Dual Path With Encouraging Direction GHK-Cu's unique dual-track regulatory path topical from Category 1 and injectable from Category 2, both heading to PCAC review before February 2027 reflects the complexity and nuance of the FDA's current approach to peptide regulation
In low-resource settings, the cost of supplements may be a barrier to their widespread use, despite the potential benefits for PCOS management
These peptides can influence cellular behavior by aiding in healing, tissue regeneration, and collagen production
Longevity & Cellular Regeneration Perhaps its most exciting benefit, GHK-Cu activates genes associated with youth and repair, promoting stem cell activation and DNA protection
In the C
Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry